Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CBFB | Q13951 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | FOXO1 | Q12778 | 2/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652546 | 0.91 | CNR1 (0.42) | CNR1CNR2CBFBEGLN1KDR | |
| SCHEMBL5651448 | 0.89 | CNR1 (0.46) | METAP2CNR1CNR2CBFBEGLN1 | |
| SCHEMBL5653369 | 0.88 | CBFB (0.44) | METAP2CNR1CNR2CBFBEGLN1 | |
| SCHEMBL5649030 | 0.87 | CBFB (0.43) | CNR1CNR2CBFBEGLN1 | |
| SCHEMBL5651558 | 0.85 | HDAC6 (0.45) | METAP2CYP1A2BRAFFOXO1PDE7A | |
| SCHEMBL5651303 | 0.84 | CBFB (0.47) | CNR1CNR2CBFBMAPTEGLN1 | |
| SCHEMBL5653611 | 0.82 | RHEB (0.49) | CNR1CNR2MAPTFOXO1PDE7A | |
| SCHEMBL5651818 | 0.80 | FOXO1 (0.42) | CNR1CNR2MAPTFOXO1PDE7A | |
| SCHEMBL5649037 | 0.80 | METAP2 (0.50) | METAP2CYP1A2CBFBMAPT | |
| SCHEMBL5650908 | 0.79 | FOXO1 (0.43) | CNR1CNR2MAPTFOXO1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | METAP2 3311/4885CYP1A2 1707/4885CNR1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.